Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...

Quest expects the new blood test will support response monitoring in clinical trials.

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Acute myeloid leukemia (AML) is a heterogeneous malignancy marked by uncontrolled proliferation of myeloid precursor cells in the bone marrow (BM) and peripheral blood, leading to cytopenias and ...

Minimal residual disease was “strongly” associated with overall survival at the patient level, researchers reported. Minimal residual disease (MRD) is “a credible intermediate endpoint” for some ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Please provide your email address to receive an email when new articles are posted on . A higher correlation was observed between MRD response and OS among non-transplanted patients vs. transplanted ...

While several targeted therapies are approved for acute myeloid leukemia, a 2023 U.K. study found that median survival following diagnosis was only about seven months, highlighting the need not only ...

(ORLANDO, Dec. 6, 2025) Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable ...

Over the past decade, flow cytometry has undergone transformative advancements, notably with the adoption of spectral flow cytometry and the emergence of next-generation imaging cytometers. These ...

FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. ...

Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh ...